Search research articles
Contact Us
Filters
Showing results (61-70 of 99) with videos related to
Page
of 10
Sort By:
JAMA Neurology
|
October 17, 2022
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
Michael J Pontecorvo, Ming Lu, Samantha C Burnham, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 16, 2025
Donanemab exposure-response in early symptomatic Alzheimer's disease
Ivelina Gueorguieva, Kay Chow, Laiyi Chua, et al.
Critical Care Medicine
|
October 25, 2011
Clinical examination for outcome prediction in nontraumatic coma
David M Greer, Jingyun Yang, Patricia D Scripko, et al.
The Laryngoscope
|
December 31, 2019
Reconstructive and prosthodontic outcomes after multiple palatomaxillary reconstructions
Kayvon F Sharif, John R Sims, Lauren E Yue, et al.
Surgical Oncology
|
March 19, 2018
Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients
John R Sims, Travis E Grotz, Barbara A Pockaj, et al.
Stem Cells (Dayton, Ohio)
|
April 9, 2009
p27Kip1 constrains proliferation of neural progenitor cells in adult brain under homeostatic and ischemic conditions
Jianhua Qiu, Yasushi Takagi, Jun Harada, et al.
Head & Neck
|
May 7, 2019
A novel approach to neurologic function sparing surgical management of vagal schwannomas: Continuous intraoperative nerve monitoring of the laryngeal adductor reflex
Mykayla L Sandler, John R Sims, Catherine Sinclair, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
September 16, 2025
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3
Roy Yaari, Karen C Holdridge, Melissa Williamson, et al.
JAMA Neurology
|
October 13, 2025
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Ming Lu, Min Jung Kim, Emily C Collins, et al.
Neurology
|
February 22, 2024
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease
Adam S Fleisher, Leanne M Munsie, David G S Perahia, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 99) with videos related to
Sort By:
Page
of 10
JAMA Neurology
|
October 17, 2022
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
Michael J Pontecorvo, Ming Lu, Samantha C Burnham, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 16, 2025
Donanemab exposure-response in early symptomatic Alzheimer's disease
Ivelina Gueorguieva, Kay Chow, Laiyi Chua, et al.
Critical Care Medicine
|
October 25, 2011
Clinical examination for outcome prediction in nontraumatic coma
David M Greer, Jingyun Yang, Patricia D Scripko, et al.
The Laryngoscope
|
December 31, 2019
Reconstructive and prosthodontic outcomes after multiple palatomaxillary reconstructions
Kayvon F Sharif, John R Sims, Lauren E Yue, et al.
Surgical Oncology
|
March 19, 2018
Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients
John R Sims, Travis E Grotz, Barbara A Pockaj, et al.
Stem Cells (Dayton, Ohio)
|
April 9, 2009
p27Kip1 constrains proliferation of neural progenitor cells in adult brain under homeostatic and ischemic conditions
Jianhua Qiu, Yasushi Takagi, Jun Harada, et al.
Head & Neck
|
May 7, 2019
A novel approach to neurologic function sparing surgical management of vagal schwannomas: Continuous intraoperative nerve monitoring of the laryngeal adductor reflex
Mykayla L Sandler, John R Sims, Catherine Sinclair, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
September 16, 2025
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3
Roy Yaari, Karen C Holdridge, Melissa Williamson, et al.
JAMA Neurology
|
October 13, 2025
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Ming Lu, Min Jung Kim, Emily C Collins, et al.
Neurology
|
February 22, 2024
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease
Adam S Fleisher, Leanne M Munsie, David G S Perahia, et al.
Page
of 10